Document Type : Letter to Editor


1 Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

2 Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran



Familial hypercholesterolemia (FH) is a genetically inherited disorder of lipid metabolism characterized by elevated levels of circulating low-density lipoprotein-cholesterol (LDL-C). High levels of LDL-C are associated with an increased risk of premature atherosclerotic cardiovascular events, aortic stenosis, xanthelasma, tendon xanthomas, and corneal arcus due to lipid deposition in various tissues 1. This autosomal dominant disease, affecting 1 in every 311 to 313 individuals worldwide, is one of the most common genetic disorders and is considered a major source of disabilities, impaired quality of life, and even death 2, 3.

1. Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation 2015; 132(22): 2167-92.
2. Hu P, Dharmayat KI, Stevens CAT, Sharabiani MTA, Jones RS, Watts GF, et al. Prevalence of familial hypercholesterolemia among the general population ‎and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Circulation 2020; 141(22): 1742-59.
3. Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol 2020; 75(20): 2553-66.
4. Hopkins PN. Putting into perspective the hazards of untreated familial hypercholesterolemia. Circulation 2017: e006553.
5. McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and treatment of heterozygous familial hypercholesterolemia. J Am Heart Assoc 2019; 8(24): e013225.
6. Lui DT, Lee AC, Tan KC. Management of Familial Hypercholesterolemia: Current Status and Future Perspectives. J Endocr Soc 2021; 5(1): bvaa1221.
7. Futema M, Plagnol V, Li K, Whittall RA, Neil HA, Seed M, et al., UK10K Consortium, Humphries SE. Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations. J Med Genet 2014;  51(8): 537-5442.
8. Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA, et al., Use of low-‎density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013; 381(9874): 1293-13013.
9. Safarova MS, Kullo IJ. My approach to the patient with familial hypercholesterolemia. Mayo Clin Proc 20164.
10. Karanchi H, Wyne K. Familial Hyperlipidemia Type 2a. 20185.
11. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al., National Lipid Association ‎recommendations for patient-centered management of dyslipidemia: part 1-executive summary. J Clin Lipidol 2014; 8(5): 473-4886.
12. Mytilinaiou M, Kyrou I, Khan M, Grammatopoulos DK, Randeva HS. Familial hypercholesterolemia: new horizons for diagnosis and effective management. Front Pharmacol 2018; 9: 7077.